% | $
Quotes you view appear here for quick access.

BioTime, Inc. Message Board

  • drwestclone drwestclone Dec 15, 2013 5:56 PM Flag

    CANCER ALERT-Here's a look at our cancer IP

    As previously announced Biotime PanC-DX Breast cancer product will be a blood diagnostic test to be released first in the EU then in the US(after 6 mo evaluation) mid 2014. Lung and Bladder coming soon after.

    Here are three key BTX patents protecting their cutting edge diagnostics products:
    -Elevated expression of cancer/testis antigen FSIP1 in ER-positive breast tumors.
    -Defining cell-matrix combination products in the era of pluripotency.
    -Identification of human embryonic progenitor cell targeting peptides using phage display.
    -COL10A1 expression is elevated in diverse solid tumor types and is associated with tumor vasculature.
    -Evaluating the genomic and sequence integrity of human ES cell lines; comparison to normal genomes.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
3.16-0.07(-2.17%)Jul 31 4:02 PMEDT